Studybox Research 510(k) Clinical Studies
Chlamydia and Gonorrhea Point-of-Care Molecular Test
Clinical and analytical performance to support substantial equivalence.
Studybox
510(k) Clinical Studies
Point-of-care molecular tests for chlamydia and gonorrhea have been cleared and waived for vaginal swabs and male urine, and the study design that supported them is now well understood: a composite reference of two or more cleared laboratory NAATs defines patient infected status, performance is reported for each organism, each specimen type and each sex, and asymptomatic and symptomatic subjects are analyzed separately. Each of those strata needs its own positives.
Gonorrhea prevalence in women attending general clinics is low, which makes the female gonorrhea arm the long pole of almost every study. Sexual health clinics supply positives but are staffed by experienced clinicians; waived settings supply the right operators but fewer positives. The site plan typically blends both, and sample size planning should model prevalence by site type rather than assuming a single rate.
- Analyte
- Chlamydia trachomatis and Neisseria gonorrhoeae nucleic acid
- Therapeutic area
- STD/STI Detection
- Specimens
- Vaginal Swab, Urine
- Intended-use settings
- urgent care, physician office, pharmacy, emergency department
- Operators
- Non-laboratory clinic staff in waived settings running a sample-to-answer molecular instrument; laboratory staff for moderate-complexity claims.
- Comparator
- Typically a patient infected status (PIS) composite reference built from two or more FDA-cleared laboratory nucleic acid amplification tests, with specimen-type-specific rules for resolving disagreement.
510(k) Studies specifics
What Changes for This Assay on This Pathway.
- The composite reference algorithm (how many cleared NAATs, which specimen types feed it, how a single discordant is resolved) must be pre-specified and is a frequent topic of pre-submission discussion.
- Each specimen type is a separate claim with its own performance table; adding rectal or pharyngeal specimens is a separate study design and population.
- Self-collected vaginal swabs are typically claimed only when compared head-to-head with clinician-collected swabs or when the reference is run on a separately collected clinician swab.
Endpoints the study must support
- Sensitivity and specificity for C. trachomatis and N. gonorrhoeae separately, by specimen type and by sex, against the composite reference, with 95% confidence intervals
- Performance in symptomatic and asymptomatic subjects separately
- Self-collected versus clinician-collected vaginal swab agreement where both are claimed
- Invalid and error rates by site in waived settings
Enrollment realities
Driven by N. gonorrhoeae positives in women, then by asymptomatic positives in each stratum; studies typically enroll thousands of subjects across many sites to fill the female gonorrhea cell, and each additional specimen type multiplies the enrollment.
How Studybox runs it
Pre-Qualified Sites, Embedded Coordinators.
Our 100+ pre-qualified U.S. sites are matched to the intended-use population and setting, with Studybox coordinators embedded on site for recruitment, consent, specimen handling, and data capture. Typical activation is about four weeks. How we run 510(k) clinical studies →
Same assay, other pathways
Relevant FDA guidance
- Recommendations for Dual 510(k) and CLIA Waiver by Application Studies
- Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices
- Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program
- Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests
FAQ
Chlamydia and Gonorrhea Point-of-Care Molecular Test Study Questions.
01 Who operates the chlamydia and gonorrhea point-of-care molecular test in a 510(k) studies study?
Non-laboratory clinic staff in waived settings running a sample-to-answer molecular instrument; laboratory staff for moderate-complexity claims.
02 What is the comparator for a chlamydia and gonorrhea point-of-care molecular test study?
Typically a patient infected status (PIS) composite reference built from two or more FDA-cleared laboratory nucleic acid amplification tests, with specimen-type-specific rules for resolving disagreement.
03 What drives enrollment for a chlamydia and gonorrhea point-of-care molecular test study?
Driven by N. gonorrhoeae positives in women, then by asymptomatic positives in each stratum; studies typically enroll thousands of subjects across many sites to fill the female gonorrhea cell, and each additional specimen type multiplies the enrollment.
Let's talk IVD research
Planning a chlamydia and gonorrhea point-of-care molecular test study?
Tell us the intended use and setting. We'll come back with a site plan, operator strategy, and a realistic activation timeline for the 510(k) studies pathway.